In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...

Pre-earnings options volume in Vertex is normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near 4.1%, or $19.25, after results are released.

After hours: February 21 at 4:20:00 PM EST Loading Chart for VERX ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is ...

In a phase 2 study, the company's medication suzetrigine barely performed better than a placebo in treating painful ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2024 results exceeding the market’s revenue expectations , with sales up 15.7% year on year to $2.91 billion. The company ...

Adjusted earnings of $1.04 billion, or $3.98 per share, fell from $1.1 billion, or $4.20 per share, a year earlier, slightly short of estimates. Vertex pointed to an increase in operating ...

A college degree is a smart choice for veterans because it furthers opportunities in the workplace and increases earning potential. A recent study by Smart Asset using the Bureau of Labors ...